DOCSLIB.ORG

Recent Advances in Intravenous Anesthesia and Anesthetics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recent Advances in Intravenous Anesthesia and Anesthetics Recent advances in intravenous anesthesia and anesthetics The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Mahmoud, Mohamed, and Keira P. Mason. 2018. “Recent advances in intravenous anesthesia and anesthetics.” F1000Research 7 (1): F1000 Faculty Rev-470. doi:10.12688/f1000research.13357.1. http:// dx.doi.org/10.12688/f1000research.13357.1. Published Version doi:10.12688/f1000research.13357.1 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:37160088 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA F1000Research 2018, 7(F1000 Faculty Rev):470 Last updated: 17 APR 2018 REVIEW Recent advances in intravenous anesthesia and anesthetics [version 1; referees: 2 approved] Mohamed Mahmoud1, Keira P. Mason 2 1Department of Anesthesiology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA 2Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children’s Hospital and Harvard Medical School, 300 Longwood Avenue, Boston, MA, 02115, USA First published: 17 Apr 2018, 7(F1000 Faculty Rev):470 (doi: Open Peer Review v1 10.12688/f1000research.13357.1) Latest published: 17 Apr 2018, 7(F1000 Faculty Rev):470 (doi: 10.12688/f1000research.13357.1) Referee Status: Abstract Invited Referees Anesthesiology, as a field, has made promising advances in the discovery of 1 2 novel, safe, effective, and efficient methods to deliver care. This review explores refinement in the technology of soft drug development, unique version 1 anesthetic delivery systems, and recent drug and device failures. published 17 Apr 2018 Keywords Intravenous Anesthesia, Midazolam, Xenon, Propofol F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published. 1 Anuj Chauhan, University of Florida, USA 2 Wensheng Zhang, Sichuan University, China Discuss this article Comments (0) Page 1 of 9 F1000Research 2018, 7(F1000 Faculty Rev):470 Last updated: 17 APR 2018 Corresponding author: Mohamed Mahmoud ([email protected]) Author roles: Mahmoud M: Writing – Original Draft Preparation, Writing – Review & Editing; Mason KP: Writing – Original Draft Preparation, Writing – Review & Editing Competing interests: No competing interests were disclosed. How to cite this article: Mahmoud M and Mason KP. Recent advances in intravenous anesthesia and anesthetics [version 1; referees: 2 approved] F1000Research 2018, 7(F1000 Faculty Rev):470 (doi: 10.12688/f1000research.13357.1) Copyright: © 2018 Mahmoud M and Mason KP. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Grant information: The author(s) declared that no grants were involved in supporting this work. First published: 17 Apr 2018, 7(F1000 Faculty Rev):470 (doi: 10.12688/f1000research.13357.1) Page 2 of 9 F1000Research 2018, 7(F1000 Faculty Rev):470 Last updated: 17 APR 2018 Introduction not occur after infusion of remimazolam because it is primarily The first generation of intravenous (IV) agents for anesthesia cleared by unique tissue esterase enzymes, which convert it into induction and maintenance, as an alternative to volatile agents, an inactive carboxylic acid metabolite (CNS7054)7,8. This novel dates back to the introduction of thiopental in the 1930’s. Since anesthetic agent has a relatively short context-sensitive half-life then, propofol, ketamine, etomidate, dexmedetomidine, and benzo- of 7–8 minutes, even after a 2-hour infusion, and, as with diazepines represent some of the more significant contributions to midazolam, can be reversed with flumazenil. IV anesthetic or sedative agents. Researchers continue to develop both new formulations of these existing agents and new chemical While remimazolam was initially developed for use as a drug for entities in strides to improve safety, predictability, efficacy, onset, procedural sedation, more studies are currently focused on utilizing and recovery profile and to minimize side effects. Novel drug this agent for the induction and maintenance of general anesthe- development is challenging, costly (2.5 billion dollars on aver- sia. A recent study examined the feasibility of delivering inhaled age), and risky1. Only 1 in 10 drugs in phase I development will go remimazolam alone or as an adjunct to remifentanil in rodents. on to obtain Food and Drug Administration (FDA) approval2, Remimazolam significantly potentiated the analgesic effect of and some drugs are withdrawn from the market, even after remifentanil, without lung irritation, bronchospasm, or other approval, because of unanticipated limitations and drawbacks. adverse pulmonary events9. Since its introduction, target-controlled infusion (TCI) technol- In the USA, the initial development of remimazolam was ogy has evolved from a research tool into a now-routine part of intended for sedation for adult colonoscopy10–12. In the EU, it anesthesia delivery in many countries (USA excluded) world- is undergoing development for general anesthesia in patients wide. Advancement in this technology has the potential to undergoing non-cardiac and cardiac surgery, including intensive expand the precision, reliability, efficacy, and safety of IV care unit (ICU) sedation for up to 24 hours after the opera- anesthesia delivery. tion. In Japan, a clinical phase III program in anesthesia has also been conducted. Remimazolam doses of 0.075 to 0.2 mg/kg This review of the literature will highlight the recent develop- showed good effect in a phase I trial for safety and efficacy8. ments and failures in drug and device innovations and novel drug Dosages for bolus or infusion are awaited. delivery systems. Remimazolam has potentially important clinical applications New innovations in drug development owing to its rapid offset of action and maintenance of stable hemo- Recent and evolving drug innovations are primarily focused on dynamics. Most of the current trials involved infusions of bolus modifying the chemical structures of existing drugs or drug classes or duration infusions; thus, additional information is required to with intent to improve their pharmacodynamic, pharmacokinetic, determine how metabolism is affected by prolonged infusions and side effect properties. The following section reviews remi- or repeat boluses. Additional studies are required to provide mazolam, etomidate, and propofol derivatives and alternatives more data on diverse patient populations (weight, age range, and which have been formulated to offer improvements on the parent comorbidities, including renal and hepatic insufficiency). It has compounds. not been studied in pregnant patients or the pediatric popula- tion. Comprehensive pharmacokinetic and pharmacodynamic Remimazolam and ADV6209 as well as safety studies are still required, and many questions Midazolam is a widely used sedative and anxiolytic administered remain to be answered before this drug can enter clinical practice. as a popular sedation choice and is used for patient care in a vari- ety of inpatient and outpatient settings. Some drawbacks to the ADV6209: new formulation of oral midazolam use of midazolam include lack of analgesia and prolonged recov- A novel formulation of oral midazolam is currently under inves- ery times in patients with liver disease. Remimazolam is a new, tigation, with phase I and II trials now started in both adults and short-acting, ester-based anesthetic agent that allows for rapid children. This innovative 0.2% aqueous midazolam solution has esterase-mediated metabolism independent of hepatic or renal been formulated by combining a sweetener (sucralose), an aroma enzymes and function3,4. It is currently in phase III clinical devel- (orange aroma), and y-cyclodextrin with a citric acid solution opment for procedural sedation in the USA. As the name implies, of midazolam13. This formulation also appears to improve the remimazolam combines the properties of two unique drugs already longevity of the oral formulation’s shelf-life (slower degrada- established in anesthesia: midazolam and remifentanil. It acts on tion)14. Initial studies indicate that the pharmacokinetic and phar- GABA receptors, as does midazolam, and exhibits pharmacokinetic macodynamic parameters are unaltered with a 0.2% midazolam properties common to the ester-based opioid remifentanil. The addi- formulation, although there are important advantages of increased tion of a benzodiazepine to remifentanil targets a hopeful synergy palatability. A recent study examined the pharmacokinetic between the two, with improved sedation and anxiolysis. In ani- characteristics of the ADV6209 oral formulation in children from mal studies, remimazolam produced a more rapid onset and faster 6 months to 18 years old, showing that the measured pharma- recovery than did midazolam5. Remimazolam is primarily cleared cokinetic parameters of ADV6029 were close to those reported by tissue esterase enzymes, carboxylesterases (CESs). CESs par- in the
Load more

Recommended publications
  • Federal Register/Vol. 79, No. 39/Thursday, February 27, 2014/Rules and Regulations
    Federal Register / Vol. 79, No. 39 / Thursday, February 27, 2014 / Rules and Regulations 10985 (2) Turkeys— Combination in Zoalene in grams/ton grams per ton Indications for use Limitations Sponsor (i) 113.5 to 170.3 ..... ................................. Growing turkeys: For prevention and con- Feed continuously as sole ration. For tur- 054771 trol of coccidiosis. keys grown for meat purposes only. Do not feed to laying birds. (ii) 113.5 to 170.3 .... Bacitracin methylene Growing turkeys: For prevention and con- Feed continuously as sole ration until 14 054771 disalicylate 4 to 50. trol of coccidiosis; and for increased to 16 weeks of age. For turkeys grown rate of weight gain and improved feed for meat purposes only. Do not feed to efficiency. laying birds. Dated: February 3, 2014. Legal Authority initiated by the Attorney General (1) on Bernadette Dunham, The DEA implements and enforces his own motion; (2) at the request of the Director, Center for Veterinary Medicine. titles II and III of the Comprehensive Secretary of the Department of Health 1 [FR Doc. 2014–02617 Filed 2–26–14; 8:45 am] Drug Abuse Prevention and Control Act and Human Services (HHS), or (3) on the petition of any interested party. 21 BILLING CODE 4160–01–P of 1970, as amended. Titles II and III are referred to as the ‘‘Controlled U.S.C. 811(a). This action is based on a Substances Act’’ and the ‘‘Controlled recommendation from the Assistant DEPARTMENT OF JUSTICE Substances Import and Export Act,’’ Secretary of the HHS and on an respectively, and are collectively evaluation of all other relevant data by Drug Enforcement Administration referred to as the ‘‘Controlled the DEA.
    [Show full text]
  • 22-244 Biopharmaceutics Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 22-244 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) DEP\RT\IE.'\T OF IIEALTH .\ '\ D Clinical Pharmacology & Biopharmaceutics IH\L\!\ SER\ICES PI HUC IIE\LTH SERVICE (HFD 870) FOOD\'\D DRIG .-\D\""ISTR\TION Tracl"ingl Action Sheet foi' Foi'malllnformai Consults . Iniiii: \rikdllih C. '\dll.lIi_ I'h.I), To: DOCl'\'IENT ROOi\l (LOG-IN and LOC-OlT) Please log-in this consult and review action for the specified IND/NDA submission 1); I I.: II I X::I)I)X ~;\~) :\u.: ND.\ :\u. :::: - ::-1-1 I),\TI 01 DOel "II.NT IIJ' 1:1/::()IJX Sni.11 :\u.: IV-IJIJIJ Class I Resuhiiission '\.\\11.01 imi(, l'I~IORln (()'\ \11)1 R\II ()'\ J).lIC ui' illl,)lli.il.;lmlldl I IJ I Y::()IJX I LlCEDR.\ (Fospropofol) Standanl (ulisLlli: Injection I 1111 :\/\\11 01 \I'O'\\OR: I \1(;1 Pharma I TYPE OF SL InIiSSIO,\ CLI'\I( .\L PIIARMACOI,O(;YIBIOPIL\R\L\CEITlCS RELATED ISSUE o I'I~I.-I:\I) 0 1)IS\OI.11 IO:\I:\-\III~O 1~1I.1 ..\SI. 0 IIN/\1. I'RI1\III) 1..\131 1.1:\( , 0\:\1\ 1\111' III \1\:\ \(\1 IN(i o 1311h \1\11./\131111 Y \ 1(1)11\ ~ L\l31I1NCi RI. VISIO'\ i:\-\iiim \111 ,\HI)I 0 1\\1 0 I "i - \ I \ 0 \\\ I \ I J( i~ Ii)l lSi o (ORRI\I)ONI)IMî o I'R()lI)(.I)1 o Si '1)\( I~II\TII) 0 IWI.(j /\I)VIRTI\I:\( j 01'11\\1.
    [Show full text]
  • Euthanasia of Experimental Animals
    EUTHANASIA OF EXPERIMENTAL ANIMALS • *• • • • • • • *•* EUROPEAN 1COMMISSIO N This document has been prepared for use within the Commission. It does not necessarily represent the Commission's official position. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu.int) Cataloguing data can be found at the end of this publication Luxembourg: Office for Official Publications of the European Communities, 1997 ISBN 92-827-9694-9 © European Communities, 1997 Reproduction is authorized, except for commercial purposes, provided the source is acknowledged Printed in Belgium European Commission EUTHANASIA OF EXPERIMENTAL ANIMALS Document EUTHANASIA OF EXPERIMENTAL ANIMALS Report prepared for the European Commission by Mrs Bryony Close Dr Keith Banister Dr Vera Baumans Dr Eva-Maria Bernoth Dr Niall Bromage Dr John Bunyan Professor Dr Wolff Erhardt Professor Paul Flecknell Dr Neville Gregory Professor Dr Hansjoachim Hackbarth Professor David Morton Mr Clifford Warwick EUTHANASIA OF EXPERIMENTAL ANIMALS CONTENTS Page Preface 1 Acknowledgements 2 1. Introduction 3 1.1 Objectives of euthanasia 3 1.2 Definition of terms 3 1.3 Signs of pain and distress 4 1.4 Recognition and confirmation of death 5 1.5 Personnel and training 5 1.6 Handling and restraint 6 1.7 Equipment 6 1.8 Carcass and waste disposal 6 2. General comments on methods of euthanasia 7 2.1 Acceptable methods of euthanasia 7 2.2 Methods acceptable for unconscious animals 15 2.3 Methods that are not acceptable for euthanasia 16 3. Methods of euthanasia for each species group 21 3.1 Fish 21 3.2 Amphibians 27 3.3 Reptiles 31 3.4 Birds 35 3.5 Rodents 41 3.6 Rabbits 47 3.7 Carnivores - dogs, cats, ferrets 53 3.8 Large mammals - pigs, sheep, goats, cattle, horses 57 3.9 Non-human primates 61 3.10 Other animals not commonly used for experiments 62 4.
    [Show full text]
  • Intravenous Anesthetics  a Drug That Induces Reversible Anesthesia  the State of Loss of Sensations, Or Awareness
    DR.MED. ABDELKARIM ALOWEIDI AL-ABBADI ASSOCIATE PROF. FACULTY OF MEDICINE THE UNIVERSITY OF JORDAN Goals of General Anesthesia Hypnosis (unconsciousness) Amnesia Analgesia Immobility/decreased muscle tone (relaxation of skeletal muscle) Reduction of certain autonomic reflexes (gag reflex, tachycardia, vasoconstriction) Intravenous Anesthetics A drug that induces reversible anesthesia The state of loss of sensations, or awareness. Either stimulates an inhibitory neuron, or inhibits an excitatory neuron. Organs are divided according to blood perfusion: High- perfusion organs (vessel-rich); brain takes up disproportionately large amount of drug compared to less perfused areas (muscles, fat, and vessel-poor groups). After IV injection, vessel-rich group takes most of the available drug Drugs bound to plasma proteins are unavailable for uptake by an organ After highly perfused organs are saturated during initial distribution, the greater mass of the less perfused organs continue to take up drug from the bloodstream. As plasma concentration falls, some drug leaves the highly perfused organs to maintain equilibrium. This redistribution from the vessel-rich group is responsible for termination of effect of many anesthetic drugs. Compartment Model Inhibitory channels : GABA-A channels ( the main inhibitory receptor). Glycine channels. Excitatory channels : Neuronal nicotic. NMDA. Rapid onset (mainly unionized at physiological pH) High lipid solubility Rapid recovery, no accumulation during prolonged infusion Analgesic
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • A Phase 3 Randomized, Double-Blind, Dose-Contro
    Clinical Review Lex Schultheis M.D., Ph.D. NDA 22-244 (000) Fospropofol Disodium Injection 10.1.3 Protocol 3000-524 A dose-controlled study in bronchoscopy patients Title: A Phase 3 randomized, double-blind, dose-controlled study to assess the efficacy and safety ofFospropofol (fospropofol disodium) injection for minimal-to-moderate sedation in patients undergoing flexible bronchoscopy Indication: minimal-to-moderate sedation Objectives: 1. demonstrate that Fospropofol is effective in providing minimal-to-moderate sedation 2. demonstrate clinical benefit of Fospropofol to patients 3. Evaluate safety ofFospropofol Study Design: Patients are to be administered 50 mcg offentanyl intravenously before beginning the procedure and before administering sedation. One additional dose of25 mcg of fentanyl may be administered after an interval of 10 minutes if the patient appears to be in pain. Randomized, double-blinded, dose-control with patients assigned 1: 1 to one of two initial sedation doses ofFospropofol: either 2 mg/kg (range 120 mg to 180 mg) or 6.5 mg/kg (range 390 to 585 mg). The initial dose offospropofol is to be administered 5 minutes after administration of the initial dose of fentanyl. The initial dose ofFospropofol and up to two additional supplemental doses may be administered at four minute intervals to achieve an OAA/S score of not more than 4/5. The supplemental doses ofFospropofol are 0.5 mg/kg (range 30-45 mg) for the patients treated with an initial dose of2 mg/kg and 1.63 mg/kg (range 97.5-146 mg) for patients treated with an initial dose of 6.5 mg/kg.
    [Show full text]
  • Clinical Anesthesia and Analgesia in Fish
    WellBeing International WBI Studies Repository 1-2012 Clinical Anesthesia and Analgesia in Fish Lynne U. Sneddon University of Liverpool Follow this and additional works at: https://www.wellbeingintlstudiesrepository.org/acwp_vsm Part of the Animal Studies Commons, Other Animal Sciences Commons, and the Veterinary Toxicology and Pharmacology Commons Recommended Citation Sneddon, L. U. (2012). Clinical anesthesia and analgesia in fish. Journal of Exotic Pet Medicine, 21(1), 32-43. This material is brought to you for free and open access by WellBeing International. It has been accepted for inclusion by an authorized administrator of the WBI Studies Repository. For more information, please contact [email protected]. Clinical Anesthesia and Analgesia in Fish Lynne U. Sneddon University of Liverpool KEYWORDS Analgesics, anesthetic drugs, fish, local anesthetics, opioids, NSAIDs ABSTRACT Fish have become a popular experimental model and companion animal, and are also farmed and caught for food. Thus, surgical and invasive procedures in this animal group are common, and this review will focus on the anesthesia and analgesia of fish. A variety of anesthetic agents are commonly applied to fish via immersion. Correct dosing can result in effective anesthesia for acute procedures as well as loss of consciousness for surgical interventions. Dose and anesthetic agent vary between species of fish and are further confounded by a variety of physiological parameters (e.g., body weight, physiological stress) as well as environmental conditions (e.g., water temperature). Combination anesthesia, where 2 anesthetic agents are used, has been effective for fish but is not routinely used because of a lack of experimental validation. Analgesia is a relatively underexplored issue in regards to fish medicine.
    [Show full text]
  • Chapter 329 [New] Uniform Controlled Substances Act
    CHAPTER 329 [NEW] UNIFORM CONTROLLED SUBSTANCES ACT Part I. General Provisions Section 329-1 Definitions 329-2 Hawaii advisory commission on drug abuse and controlled substances; number; appointment 329-3 Annual report 329-4 Duties of the commission Part II. Standards and Schedules 329-11 Authority to schedule controlled substances 329-12 Nomenclature 329-13 Schedule I tests 329-14 Schedule I 329-15 Schedule II tests 329-16 Schedule II 329-17 Schedule III Tests 329-18 Schedule III 329-19 Schedule IV tests 329-20 Schedule IV 329-21 Schedule V tests 329-22 Schedule V 329-23 Republishing and distribution of schedules Part III. Regulation of Manufacture, Distribution, Prescription, and Dispensing of Controlled Substances 329-31 Rules 329-31.5 Clinics 329-32 Registration requirements 329-33 Registration 329-34 Revocation and suspension of registration 329-35 Order to show cause 329-36 Records of registrants 329-37 Filing requirements 329-38 Prescriptions 329-39 Labels 329-40 Methadone treatment programs Part IV. Offenses and Penalties 329-41 Prohibited acts B-penalties 329-42 Prohibited acts C-penalties 329-43 Penalties under other laws 329-43.5 Prohibited acts related to drug paraphernalia Amended 0612 1 329-44 Notice of conviction to be sent to licensing board, department of commerce and consumer affairs 329-45 Repealed 329-46 Prohibited acts related to visits to more than one practitioner to obtain controlled substance prescriptions 329-49 Administrative penalties 329-50 Injunctive relief Part V. Enforcement and Administrative Provisions 329-51 Powers of enforcement personnel 329-52 Administrative inspections 329-53 Injunctions 329-54 Cooperative arrangements and confidentiality 329-55 Forfeitures 329-56 Burden of proof; liabilities 329-57 Judicial review 329-58 Education and research 329-59 Controlled substance registration revolving fund; established Part VI.
    [Show full text]
  • Bolus-Dose Fospropofol Disodium (Lusedra®)
    a & hesi C st lin e ic n a A l f R o e l s Journal of Anesthesia & Clinical e a a n r r c u h o Leslie et al., J Anesth Clin Res 2015, 6:8 J ISSN: 2155-6148 Research DOI: 10.4172/2155-6148.1000552 Research Article Open Access Bolus-Dose Fospropofol Disodium (Lusedra®): Is 10 mg/Kg Superior To 6.5 mg/Kg for Sedation in Patients Undergoing Regional Anesthesia Blocks Prior to Orthopedic Surgery? John B Leslie1*, Terrence L Trentman1, Lopa Misra1, David M Rosenfeld1, David P Seamans1, Renee E Caswell1, André R Watkins1, Joseph G Hentz1 and Ryan Buckley2 1Mayo Medical School – Phoenix Campus, Mayo Clinic Arizona, Scottsdale, Arizona, USA 2University of Arizona School of Medicine – Tucson Campus, Tucson, Arizona, USA *Corresponding author: John B Leslie, MD, MBA, Department of Anesthesiology, Mayo Clinic Hospital; 5777 East Mayo Boulevard, Phoenix, AZ 85054-4502, USA, Tel: 480-342-1800; Fax: 480-342-2319; E-mail: [email protected] Received date: February 27, 2015, Accepted date: August 11, 2015, Published date: August 18, 2015 Copyright: © 2015 Leslie JB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Objective: Fospropofol disodium (Lusedra®) is a pro-drug propofol for Monitored Anesthesia Care. The FDA- approved dose regimen is minimally effective with a slow onset often requiring supplemental doses at 4 minutes to achieve adequate sedation and frequently requires early re-dosing.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • The Effectiveness of Ketamine As an Anesthetic for Fish (Rainbow Trout – Oncorhynchus Mykiss)
    Research Article Oceanogr Fish Open Access J Volume 13 Issue 1 - January 2021 Copyright © All rights are reserved by Mohammedsaeed Ganjoor DOI: 10.19080/OFOAJ.2021.13.555852 The Effectiveness of Ketamine as an Anesthetic for Fish (Rainbow Trout – Oncorhynchus mykiss) Mohammedsaeed Ganjoor*, Maysam Salahi-ardekani, Sajad Nazari, Javad Mahdavi, Esmail Kazemi and Mohsen Mohammadpour Genetic and Breeding Research Centre for Cold Water Fishes (ShahidMotahary Cold-water Fishes Center), Iranian Fisheries Science Research Institute, Iran Submission: November 03, 2020; Published: January 12, 2021 Corresponding author: Mohammedsaeed Ganjoor, Genetic and Breeding Research Centre for Cold Water Fishes (ShahidMotahary Cold-water Fishes Center), Iranian Fisheries Science Research Institute, Agricultural Research Education and Extension Organization (AREEO), Yasuj, IRAN Email: [email protected] & [email protected] Abstract Ketamine was evaluated as water-soluble anesthetics drug for a species of fish, rainbow trout (Oncorhynchus mykiss). Fish (size ~20 - ~240 anesthesiagr.) were exposed duration to (stage1 a 100-ppm to 3) concentrationand recovery duration of Ketamine was recorded.solution (dissolved Also, surveillance in water), was they evaluated were arranged after recovery. in 4 treatments Ketamine wasbased effective on their to weight range (Treatment-1= 22.8±3.4 g; Treatment-2= 51.7±4.4 g; Treatment-3= 69.8±5.2 g and Treatment-4= 243.8±20.7 g). Elapsed time for cause anesthesia in the fish as 100 ppm concentration. 10 fishes of each treatment (%100) were anesthetized and were induced in stageIII-Plane3 of anesthesia within 2-3 min after exposure to anesthetic solution (Treatment-1= 110.3±3.5 seconds; Treatment-2= 140.0±5.9 sec; Treatment-3= 180.0±5.8 sec and Treatment-4= 190.0±5.8 sec).
    [Show full text]
  • Capítulo 30 Anestesia Intravenosa
    Capítulo 30 Anestesia intravenosa JAAP VUYK • ELSKE SITSEN • MARIJE REEKERS Agradecimientos. Los redactores y el editor desean agradecer a los Dres. J. G. Reves, Peter Glass, David A. Lubarsky, Matthew D. McEvoy y Ricardo Martinez-Ruiz la aportación de un capítulo sobre el mismo tema en la edición previa de este tratado, que ha servido de base para el presente capítulo. P UNTOS CLAVE • La introducción de tiopental en la práctica clínica en 1934 supuso el comienzo de la era de la anestesia intravenosa (i.v.) moderna. Hoy en día, los anestésicos i.v. forman parte de la inducción y el mantenimiento de la anestesia y la sedación en un amplio abanico de situaciones. • El anestésico i.v. más utilizado es el propofol, un alquilfenol formulado en emulsión lipídica. Se trata de un fármaco que ofrece rapidez de inicio y finalización de acción, así como tiempos decrecientes concordantes con el contexto de unos 10 min en infusiones de duración menor de 3 h e inferior a 40 min en aquellas de hasta 8 h. Su mecanismo de acción podría corresponder a la potenciación de las corrientes de cloro inducidas por el ácido g-aminobutírico (GABA). El propofol induce una disminución dependiente de la dosis de la presión arterial media por sendas reducciones del gasto cardíaco y la resistencia vascular periférica, y ocasiona una depresión respiratoria moderada. El efecto antiemético constituye un rasgo exclusivo de este compuesto incluso a concentraciones menores de las que producen sedación. • Los barbitúricos constituían los fármacos i.v. más utilizados en la inducción de la anestesia con anterioridad a la introducción del propofol.
    [Show full text]